Fisetin

Research use only, not for human use.

Extracted from Rhus succedanea L;Store the product in sealed, cool and dry condition.

Extracted from Rhus succedanea L;Store the product in sealed, cool and dry condition.(In Vitro):Fisetin inhibits lipid accumulation and suppresses the expression of PPARγ in 3T3-L1 cells. Fisetin suppresses early stages of preadipocyte differentiation, and induces expression of Sirt1. Fisetin facilitates Sirt1-mediated deacetylation of PPARγ and FoxO1, and enhances the association of Sirt1 with the PPARγ promoter, leading to suppression of PPARγ transcriptional activity, thereby repressing adipogenesis. Fisetin binds to tubulin and stabilizes microtubules with binding characteristics far superior than paclitaxel. Fisetin treatment of human prostate cancer cells results in robust up-regulation of microtubule associated proteins (MAP)-2 and -4. Fisetin significantly inhibits PCa cell proliferation, migration, and invasion. Nudc, a protein associated with microtubule motor dynein/dynactin complex that regulates microtubule dynamics, is inhibited with Fisetin treatment.(In Vivo):Fisetin treatment to UVB exposed mice results in decreased hyperplasia and reduces infiltration of inflammatory cells. Fisetin treatment also reduces inflammatory mediators such as COX-2, PGE2 as well as its receptors (EP1- EP4), and MPO activity. Furthermore, Fisetin reduces the level of inflammatory cytokines TNFα, IL-1β and IL-6 in UVB exposed skin. Fisetin treatment also reduces cell proliferation markers as well as DNA damage as evidenced by increased expression of p53 and p21 proteins.

——

——

CI-75620 | NSC 407010 | NSC 656275

Chromatin/Epigenetic

Sirtuin

SIRT

Other Indications

——

528-48-3

286.24

C15H10O6

>98% (HPLC)

Ethanol: 3 mg/mL (10.48 mM); DMSO: 57 mg/mL (199.13 mM)

O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC=C13

2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one

(-20℃)

With Ice Pack

≥ 2 years